James Reilly (Dublin North, Fine Gael)

I propose to take Questions Nos. 113, 609, 615, 654, 672 and 695 together.

The manufacturer of fingolimod, Gilenya®, has submitted an application to the Health Service Executive for the product to be reimbursed through community pharmacies under the high-tech drug scheme. The list of medicinal products provided under the scheme is reviewed on a regular basis. The application in respect of the product in question is under consideration.

The HSE has identified the potential for a significant budget impact with this product and it has, therefore, been referred to the HSE drugs group which examines how new medicines can be introduced into clinical care pathways as and when resources become available. In addition, the chief medical officer has been requested to engage with the HSE to examine the current decision making process and ensure a robust system is in place to drive decision making around medicines and evidence based prescribing. It is expected that the chief medical officer will report on this matter in the coming weeks.

I am pleased to inform Deputies that we have agreed with the pharmaceutical companies on a sum of moneys to be reimbursed to us which will allow us to open negotiations on a more comprehensive deal and release the new drugs in question.

See this speech in context